A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
35 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed with type 2 diabetes for at least 6 months
Blood glucose criteria must be met
BMI in the range 22-40
History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
Use of thiazolidinediones or need for insulin within 3 months prior to screening
Significant concomitant diseases or complications of diabetes
High fasting triglycerides as defined by the protocol
Other protocol-defined inclusion/exclusion criteria may apply